Andrew Owen

This study evaluates the pharmacokinetics, biodistribution, and therapeutic efficacy of a trimeric nanobody against SARS-CoV-2 in golden Syrian hamsters, showing that intranasal administration provides effective respiratory exposure and therapeutic benefit.

This study evaluates the efficacy of a single dose of long-acting sorfequiline in a mouse model for tuberculosis preventive therapy.

This study optimizes favipiravir doses against RNA viruses using physiologically-based pharmacokinetic modeling, showing safe dosing ranges and effects of chronic kidney disease.

This study investigates the biodistribution and effects of Ronapreve in a mouse model of SARS-CoV-2 infection, showing it does not reach the brain but reduces viral loads in the lung and brain.

This paper evaluates the efficacy of multimeric bicyclic peptides as antiviral agents in preclinical SARS-CoV-2 models, showing significant reduction in viral burden across multiple therapeutic settings.

This study compares static and dynamic flow culture conditions in human airway models to show that dynamic flow improves tissue architecture, infection dynamics, and predictive power for SARS-CoV-2 infection.

This study examines how molnupiravir and nirmatrelvir affect SARS-CoV-2 genome diversity in immunocompromised mice, finding reduced viral load and specific mutations but no major consensus sequence changes.

This study evaluates how hyaluronidase affects the release and pharmacokinetics of a long-acting injectable drug in mice and rats.

The paper investigates NAT2 polymorphisms and their effect on isoniazid pharmacokinetics in HIV-infected South Africans with tuberculosis, finding no significant genotype-phenotype correlation.